Physician profile
Tanjit Kaur
NPI 1902505423
$339.19
in general payments reported to CMS, 2019-2025
13 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $143 · 2024: $73.93 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $339.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $47.15 | 2024-2025 | Doc Band |
| Nestle Healthcare Nutrition INC. | $38.00 | 2023 | |
| Merck Sharp & Dohme LLC | $34.16 | 2024 | Vaxneuvance, Gardasil 9, M-M-R II |
| Seqirus USA INC | $33.03 | 2024-2025 | Flucelvax |
| Glaxosmithkline, LLC. | $29.96 | 2023-2025 | Bexsero, Rotarix |
| Sanofi-Aventis U.S. LLC | $28.10 | 2025 | |
| Ironshore Pharmaceuticals INC. | $23.07 | 2023 | Jornay Pm |
| Corium, LLC | $21.89 | 2023 | Azstarys |
| Phadia US INC. | $19.94 | 2025 | Immunocap |
| Verrica Pharmaceuticals INC. | $19.80 | 2025 | Ycanth |
| Pfizer INC. | $15.28 | 2023 | |
| Alk-Abello, INC | $14.63 | 2023 | Odactra, Grastek |
| Sanofi Pasteur INC. | $14.18 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanjit Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.